Kinase/Enzyme Assays
Decoding the kinome with prime kinase assays
Comprehensive kinome screening is paramount for identifying selective and potent kinase inhibitors. Precise determination and subsequent optimization of compound selectivity through robust, kinome-wide screening is a cornerstone of novel kinase inhibitor discovery. This approach mitigates unwanted off-target effects associated with both kinases and non-kinase interactions, ultimately enhancing therapeutic efficacy and reducing adverse effects.
With over 400 kinases and enzymes available, PharmaLegacy provides you with a comprehensive stage for identifying and optimizing potent, selective inhibitors. We offer compound screening and SAR analysis for nuanced insights, kinase panel customization to tailor your approach, and the expertise to validate and develop assays for even the most novel targets. Our high-throughput 384-well format accelerates the pace of discovery, ensuring swift identification of promising leads.
MODELS / SERVICES
Validation Steps:
- Enzyme Titration (Time Course)
- Apparent ATP Km Determination (N=2)
- Enzyme Titration with Time Course at Apparent ATP Km
- Enzyme Titration with Time Course at 10-fold Apparent ATP Km
- DMSO Tolerance Test
- Plate Uniform Test (N=2)
- Reference compound IC50 Test (N=2)
- Enzyme Activity Site Titration (N=2)
- Validation Compounds Set Test (N=2)
- Carboxylase
- DNA polymerase
- GTPase
- Hydrolase
- Nicotinamide
- Nucleotidase
- Oxidase
- Phosphatase
- Phosphohydrolase
- Phosphoribosyltransferase
- Protease
- Bromodomain-containing protein binding partner assays
- Histone acetyltransferase
- Histone lysine demethylase
- Histone methyltransferase
- Protein arginine methyltransferase
- ADP-Glo
- AhphaELISA
- FI
- FP
- HTRF
- TR-FRET
- & More
Committed to quality:
- FDA part 11 compliant
- Animal studies strictly follow AAALAC and ILAC guidelines
- Electronically managed, traceable research data
- Rigorous adherence to international GLP and QA best practices
- Clients have real-time remote monitoring of studies
Want your scientific discoveries to become treatments? PharmaLegacy’s the right partner for you.
Providing Better Data For Critical Oncology Pipeline Decisions
To advance a compound from discovery to clinical, or to halt its development, is a huge and costly decision. For the benefit of you and your company, and for the well-being of patients in need of treatment, that decision needs to be based on correct information.
Download our Integrated In Vitro Oncology Assays brochure and see why over 300 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical oncology pipeline decisions.
We’re ready when you are.
Tell us your pharmacology challenges.
